Study Summary
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors combined with CD19 positive feeder T cells treatment for CD19+ acute lymphoblastic leukemia patients in remission .
Want to learn more about this trial?
Request More InfoInterventions
CD19 CAR-T cells and CD19 positive feeder T cellsBIOLOGICAL
Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The first affiliated hospital of soochow university | Suzhou | Jiangsu | China |
| The first affiliated hospital of soochow university | Suzhou | Jiangsu | China |
| The First Affiliated Hospital of Soochow University | Suzhou | China |